Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 145 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 3 Interventional Results available

Citalopram for Agitation in Alzheimer's Disease

NCT00898807
Conditions
Alzheimer's Disease, Agitation
Interventions
citalopram, placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
Not listed
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 4 more
Conditions
Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Conditions
Agitation, Dementia
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
65 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Phoenix, Arizona • Long Beach, California • Daytona Beach, Florida + 8 more
Conditions
Alzheimer's Disease
Interventions
Group 1 ELND005, Group 2 ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more
Conditions
Agitation Associated With Alzheimer's Disease Dementia
Interventions
EXV-802, Placebo, EXV-801
Drug
Lead sponsor
Exciva GmbH
Industry
Eligibility
55 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Murrieta, California • Indianapolis, Indiana • Flowood, Mississippi + 6 more
Conditions
Iron Deficiency, Restless Leg Syndrome
Interventions
Probiotics, Placebo
Dietary Supplement
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
5 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Agitation, Schizophrenia
Interventions
Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more
Conditions
Agitation, Dementia
Interventions
Depakote ER, Seroquel
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Conditions
Dementia Moderate, Dementia Severe, Agitation,Psychomotor, Behavioral Symptoms
Interventions
Dronabinol
Drug
Lead sponsor
Ralph H. Johnson VA Medical Center
Federal
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
46
States / cities
Phoenix, Arizona • Anaheim, California • Costa Mesa, California + 36 more
Conditions
Depressive Disorder, Mood Disorder, Psychomotor Agitation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Alzheimer Disease, Agitation
Interventions
KarXT, KarX-EC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more
Completed Not applicable Interventional Results available

Actigraphic Analysis of Treatment Response

NCT00723580
Conditions
Sleep Disorders, Circadian Rhythm, Insomnia, Psychomotor Agitation
Interventions
risperidone
Drug
Lead sponsor
Child Psychopharmacology Institute
Other
Eligibility
2 Years to 10 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Conditions
Alzheimer's Disease
Interventions
ELND005, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 50 more
Conditions
Psychosis, Dementia, Aggression, Agitation, Alzheimer Dementia
Interventions
MP-101, Placebo
Drug
Lead sponsor
Mediti Pharma Inc.
Other
Eligibility
50 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Pasadena, California • Fairfield, Connecticut + 14 more
Conditions
Alzheimer's Disease
Interventions
Memesto
Device
Lead sponsor
Edgewater Safety Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Opioid Withdrawal
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Lakes, Florida • Marlton, New Jersey • New York, New York
Conditions
Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
Interventions
Sublingual film containing Dexmedetomidine (BXCL501), Placebo Film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
Conditions
Patients With Schizophrenia and Acute Agitation
Interventions
Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, Inhaled placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Dementia, Aggression, Agitation
Interventions
ECT treatment, Standard Care (Non-ECT group)
Other
Lead sponsor
Pine Rest Christian Mental Health Services
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Grand Rapids, Michigan
Conditions
Agitation, Alzheimer Disease
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 52 more
Conditions
Music Therapy for Pain and Sedation
Interventions
provide headphones with music playing, Sounds
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California